Safety and Feasibility of Low-Dose Apatinib Combined with S-1 as the Second-Line Therapy or Beyond in Chinese Patients with Pulmonary and Hepatic Metastasis of Nasopharyngeal Carcinoma
Liya Zhou,* Jie Lin,* Gang Wu, Jiawei Chen, Xiaopeng Huang, Shuai Zhang Department of Radiation Oncology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, Hainan Province 570311, People’s Republic of China*These authors contributed equally to this w...
Main Authors: | Zhou L, Lin J, Wu G, Chen J, Huang X, Zhang S |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-03-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/safety-and-feasibility-of-low-dose-apatinib-combined-with-s-1-as-the-s-peer-reviewed-article-DDDT |
Similar Items
-
Etiology and management of nasopharyngeal hemorrhage after radiotherapy for nasopharyngeal carcinoma
by: Zhan J, et al.
Published: (2019-03-01) -
The efficacy and safety of apatinib plus capecitabine in platinum-refractory metastatic and/or recurrent nasopharyngeal carcinoma: a prospective, phase II trial
by: Lin-Quan Tang, et al.
Published: (2023-03-01) -
Apatinib combined with camrelizumab in the treatment of recurrent/metastatic nasopharyngeal carcinoma: a prospective multicenter phase II study
by: Yunyan Mo, et al.
Published: (2024-01-01) -
Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma
by: Xie L, et al.
Published: (2020-01-01) -
Prognosis of Extracapsular Spread of Cervical Lymph Node Metastases in Nasopharyngeal Carcinoma
by: Xue Yin, et al.
Published: (2020-09-01)